Effect of Risankizumab on Patient-Reported Outcomes in Moderate to Severe Psoriasis: The UltIMMa-1 and UltIMMa-2 Randomized Clinical Trials

Two identical 52-week RCTs (n=997) showed superior and statistically significant effect of risankizumab vs. placebo and ustekinumab in relieving and eliminating plaque psoriasis symptoms, improving health-related quality of life, and reducing psychological distress.

SPS commentary:

At week 16, a significantly greater proportion of patients on risankizumab than those treated with ustekinumab or placebo achieved Psoriasis Symptom Scale total score =  0, indicating no psoriasis symptoms (30.3% [181/598], 15.1% [30/199], 1.0% [2/200], both p<0 .001), and Dermatology Life Quality Index = 0 or 1 indicating no impact on skin-related HRQL (66.2%, 44.7%, 6.0%, p<0.001).

JAMA Dermatology